HK1073608A1 - Treatment of alpha-galactosidase a deficiency - Google Patents

Treatment of alpha-galactosidase a deficiency

Info

Publication number
HK1073608A1
HK1073608A1 HK05106677.2A HK05106677A HK1073608A1 HK 1073608 A1 HK1073608 A1 HK 1073608A1 HK 05106677 A HK05106677 A HK 05106677A HK 1073608 A1 HK1073608 A1 HK 1073608A1
Authority
HK
Hong Kong
Prior art keywords
deficiency
galactosidase
alpha
treatment
methods
Prior art date
Application number
HK05106677.2A
Other languages
English (en)
Inventor
Douglas A Treco
Kenneth Loveday
Marianne Borowski
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of HK1073608A1 publication Critical patent/HK1073608A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
HK05106677.2A 2002-04-25 2005-08-03 Treatment of alpha-galactosidase a deficiency HK1073608A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37558402P 2002-04-25 2002-04-25
PCT/US2003/013063 WO2003090695A2 (en) 2002-04-25 2003-04-25 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
HK1073608A1 true HK1073608A1 (en) 2005-10-14

Family

ID=29270665

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05106677.2A HK1073608A1 (en) 2002-04-25 2005-08-03 Treatment of alpha-galactosidase a deficiency

Country Status (13)

Country Link
US (6) US20040071686A1 (de)
EP (2) EP1503788B1 (de)
JP (5) JP5570677B2 (de)
AT (1) ATE514430T1 (de)
AU (2) AU2003228722B2 (de)
BR (2) BRPI0309665B8 (de)
CA (1) CA2483270C (de)
DK (1) DK1503788T3 (de)
ES (1) ES2367257T3 (de)
HK (1) HK1073608A1 (de)
IL (4) IL164757A0 (de)
NZ (1) NZ536361A (de)
WO (1) WO2003090695A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ES2376777T3 (es) 2004-09-07 2012-03-16 Velico Medical, Inc. Aparato para prolongar la supervivencia de plaquetas
JP5123663B2 (ja) * 2004-10-15 2013-01-23 ベリコ メディカル インコーポレイティッド 血小板の生存延長のための組成物および方法
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
EP2121005A1 (de) * 2006-12-21 2009-11-25 Academisch Ziekenhuis bij de Universiteit van Amsterdam Behandlung von morbus fabry
WO2009024977A2 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
WO2009032171A1 (en) * 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
US20120230974A1 (en) * 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
RU2626514C2 (ru) * 2010-06-25 2017-07-28 Шир Хьюман Дженетик Терапис, Инк. Доставка к цнс лечебных агентов
EP3964230A1 (de) 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Verfahren und zusammensetzungen zur abgabe der arylsulfatase a in das zns
NZ702808A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
PT3626257T (pt) 2010-06-25 2021-11-12 Shire Human Genetic Therapies Métodos e composições de arilsulfatase a para a administração no snc
WO2012094346A2 (en) 2011-01-03 2012-07-12 The Regents Of The University Of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
EP2665814B1 (de) 2011-01-20 2017-05-17 Protalix Ltd. Nukleinsäurekonstrukt zur expression von alpha-galaktosidase bei pflanzen und pflanzenzellen
CN103635590A (zh) * 2011-07-14 2014-03-12 基立福有限公司 蛋白质唾液酸化的快速和准确分析
KR20140098780A (ko) 2011-11-11 2014-08-08 뉴로이네이블링 테크놀로지스, 인크. 운동, 감각, 자율적, 성적, 혈관운동 및 인식 기능의 복원을 가능하게 하기 위한 비침습성 신경조절 디바이스
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en) * 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
WO2015048563A2 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
MX2016005572A (es) * 2013-10-31 2016-12-09 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
PL3237621T3 (pl) * 2014-12-22 2023-10-30 Codexis, Inc. Warianty ludzkiej alfa-galaktozydazy
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017170896A1 (ja) * 2016-03-30 2017-10-05 国立大学法人徳島大学 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
BR112019013920A2 (pt) * 2017-01-05 2020-02-04 Protalix Ltd método para tratar doença de fabry, e, forma unitária de dosagem.
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
EP3974021B1 (de) 2017-06-30 2023-06-14 ONWARD Medical N.V. System zur neuromodulierung
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
US11992684B2 (en) 2017-12-05 2024-05-28 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
EP3653256B1 (de) 2018-11-13 2022-03-30 ONWARD Medical N.V. Steuerungssystem zur bewegungsrekonstruktion und/oder wiederherstellung für einen patienten
JP2022515742A (ja) 2018-12-20 2022-02-22 コデクシス， インコーポレイテッド α－ガラクトシダーゼバリアント
EP3695878B1 (de) 2019-02-12 2023-04-19 ONWARD Medical N.V. System zur neuromodulierung
DE19211698T1 (de) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
EP4110926A4 (de) * 2020-02-28 2024-06-19 Codexis, Inc. Menschliche alpha-galactosidasevarianten

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658567A (en) * 1899-10-14 1900-09-25 Elmer G Howard Threshing-machine attachment.
US4407957A (en) * 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3580384D1 (de) 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
DK0446315T3 (da) * 1989-09-05 1998-01-05 Biotech Australia Pty Ltd Fremgangsmåde til fremstilling af PAI-2
JP2688854B2 (ja) 1989-10-27 1997-12-10 株式会社ホーネンコーポレーション 糖転移活性の強いα―ガラクトシダーゼの製造法
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
JPH06502071A (ja) 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
WO1992013067A1 (en) 1991-01-21 1992-08-06 Genzyme Corporation Production of enzymatically active glucocerebrosidase from recombinant cells
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
JPH06503479A (ja) 1991-10-16 1994-04-21 オラージェン，　インコーポレイテッド 動物体細胞の粒子−媒介トランスフォーメーション
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
JPH09508783A (ja) * 1993-09-23 1997-09-09 ニユー・イングランド・バイオレイブス・インコーポレイテツド 新規なグリコシダーゼの単離及び組成物
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
HU230275B1 (hu) 1996-09-13 2015-11-30 Shire Human Genetic Therapies, Inc Eljárás tisztított humán alfa-galaktozidáz-A készítmények előállítására, és a tisztított készítményeket tartalmazó gyógyászati készítmények, alfa-gal-A-deficienciából eredő rendellenességek kezelésében történő alkalmazásra
PL343732A1 (en) 1998-05-07 2001-09-10 Transkaryotic Therapies Modifying the expression of the fsh beta gene by homologous recombination
WO1999057291A1 (en) 1998-05-07 1999-11-11 Transkaryotic Therapies, Inc. Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
AU2003228722B2 (en) * 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency

Also Published As

Publication number Publication date
US11116823B2 (en) 2021-09-14
US10245304B2 (en) 2019-04-02
US9267166B2 (en) 2016-02-23
AU2009217430B2 (en) 2012-10-18
BR122017016940B8 (pt) 2021-07-27
IL257056B (en) 2021-03-25
EP1503788A4 (de) 2008-09-03
IL280818B (en) 2021-12-01
EP2361631A1 (de) 2011-08-31
US9523113B2 (en) 2016-12-20
AU2009217430A1 (en) 2009-10-15
WO2003090695A3 (en) 2004-05-06
IL220043B (en) 2018-02-28
NZ536361A (en) 2008-05-30
US20190255156A1 (en) 2019-08-22
ATE514430T1 (de) 2011-07-15
JP2005538941A (ja) 2005-12-22
US20110002908A1 (en) 2011-01-06
EP1503788B1 (de) 2011-06-29
JP6225224B2 (ja) 2017-11-01
ES2367257T3 (es) 2011-10-31
IL280818A (en) 2021-04-29
IL220043A0 (en) 2012-06-28
IL257056A (en) 2018-06-28
CA2483270A1 (en) 2003-11-06
JP2018016630A (ja) 2018-02-01
AU2003228722B2 (en) 2009-06-25
BRPI0309665B8 (pt) 2021-05-25
US7833742B2 (en) 2010-11-16
JP5570677B2 (ja) 2014-08-13
JP2012140431A (ja) 2012-07-26
US20040071686A1 (en) 2004-04-15
IL164757A0 (en) 2005-12-18
US20170216411A1 (en) 2017-08-03
BRPI0309665B1 (pt) 2019-07-16
BR122017016940B1 (pt) 2020-11-10
EP1503788A2 (de) 2005-02-09
DK1503788T3 (da) 2011-10-17
JP5981151B2 (ja) 2016-08-31
JP2016180003A (ja) 2016-10-13
JP2014196343A (ja) 2014-10-16
JP6492139B2 (ja) 2019-03-27
WO2003090695A2 (en) 2003-11-06
US20060177433A1 (en) 2006-08-10
BR0309665A (pt) 2005-08-16
CA2483270C (en) 2015-03-31
US20160184409A1 (en) 2016-06-30
AU2003228722A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
IL280818A (en) Methods of production of alpha-galactosides preparations
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
PL374865A1 (en) Treatment of tnf alpha related disorders
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
HK1086027A1 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
GB0201674D0 (en) Medical treatment
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
GB0218879D0 (en) Medical treatment
PT1603584E (pt) Aplidina para o tratamento de mieloma múltiplo
SI1606233T1 (sl) Fosfolipidni estri klofarabina
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
AU2003229876A8 (en) Tumour associated antigens
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
ZA200103745B (en) Therapeutic light source and method.
ZA200103743B (en) Therapeutic light source and method.
UA32314A (uk) Спосіб лікування некротичного панкреатиту
GB0118564D0 (en) Therapeutic treatment for tinnitus
UA34375A (uk) Спосіб лікування рака молочної залози
ZA200408071B (en) Combination therapy for the treatment of cancer.
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
GB0220913D0 (en) Medical treatment
GB0220849D0 (en) Medical treatment
GB0220912D0 (en) Medical treatment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230424